Home LiteratureArticle Details
PMID: 9950685 Published · ppublish English Journal Article Research Support, U.S. Gov't, P.H.S.

Novel regulation of type IV collagenase (matrix metalloproteinase-9 and -2) activities by transforming growth factor-beta1 in human prostate cancer cell lines.

Molecular biology of the cell ·Vol. 10 ·No. 2 ·1999-02-00 ·Pages 407-16

Sehgal I, Thompson TC

Abstract

The type IV collagenases/gelatinases matrix metalloproteinase-2 (MMP-2) and MMP-9 play a variety of important roles in both physiological and pathological processes and are regulated by various growth factors, including transforming growth factor-beta1 (TGF-beta1), in several cell types. Previous studies have suggested that cellular control of one or both collagenases can occur through direct transcriptional mechanisms and/or after secretion through proenzyme processing and interactions with metalloproteinase inhibitors. Using human prostate cancer cell lines, we have found that TGF-beta1 induces the MMP-9 proenzyme; however, this induction does not result from direct effects on gene transcription but, instead, through a protein synthesis-requiring process leading to increased MMP-9 mRNA stability. In addition, we have examined levels of TGF-beta1 regulation of MMP-2 in one prostate cancer cell line and found that TGF-beta1 induces higher secreted levels of this collagenase through increased stability of the secreted 72-kDa proenzyme. These results identify two novel nontranscriptional pathways for the cellular regulation of MMP-9 and MMP-2 collagenase gene expression and activities.

MeSH Terms
Collagenases/genetics,metabolism Cycloheximide/pharmacology Dactinomycin/pharmacology Gelatinases/genetics,metabolism Gene Expression Regulation, Enzymologic Gene Expression Regulation, Neoplastic Humans Male Matrix Metalloproteinase 2 Matrix Metalloproteinase 9 Metalloendopeptidases/genetics,metabolism Nucleic Acid Synthesis Inhibitors/pharmacology Prostatic Neoplasms/enzymology,genetics Protein Synthesis Inhibitors/pharmacology RNA Processing, Post-Transcriptional/drug effects RNA, Messenger/genetics,metabolism RNA, Neoplasm/genetics,metabolism Transcriptional Activation/drug effects Transforming Growth Factor beta/pharmacology Tumor Cells, Cultured
Chemicals
Nucleic Acid Synthesis Inhibitors Protein Synthesis Inhibitors RNA, Messenger RNA, Neoplasm Transforming Growth Factor beta Dactinomycin Cycloheximide Collagenases Gelatinases Metalloendopeptidases Matrix Metalloproteinase 2 Matrix Metalloproteinase 9
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Sehgal I
Scott Department of Urology, Department of Cell Biology, Baylor College of Medicine, Houston, Texas 77030, USA.
Thompson T C
References (51)
51 references, click to expand
  1. Autocrine induction of tumor protease production and invasion by a metallothionein-regulated TGF-beta 1 (Ser223, 225).
    EMBO J. 1992 Apr;11(4):1599-605 PMID: 1314170
  2. AU RNA-binding factors differ in their binding specificities and affinities.
    J Biol Chem. 1992 Mar 25;267(9):6302-9 PMID: 1532580
  3. Alterations in mRNA levels for growth-related genes after transplantation into castrated hosts in oncogene-induced clonal mouse prostate carcinoma.
    Mol Carcinog. 1992;5(1):52-61 PMID: 1543541
  4. Tumor cell invasion inhibited by TIMP-2.
    J Natl Cancer Inst. 1991 Jun 5;83(11):775-9 PMID: 1645772
  5. Transcriptional and post-transcriptional regulation of 72-kDa gelatinase/type IV collagenase by transforming growth factor-beta 1 in human fibroblasts. Comparisons with collagenase and tissue inhibitor of matrix metalloproteinase gene expression.
    J Biol Chem. 1991 Jul 25;266(21):14064-71 PMID: 1649834
  6. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation.
    Cell. 1991 Jan 25;64(2):327-36 PMID: 1703045
  7. Identification of regulatory sequences in the type 1 plasminogen activator inhibitor gene responsive to transforming growth factor beta.
    J Biol Chem. 1991 Dec 5;266(34):23048-52 PMID: 1744101
  8. Matrix metalloproteinases and their inhibitors in connective tissue remodeling.
    FASEB J. 1991 May;5(8):2145-54 PMID: 1850705
  9. Protein synthesis inhibition stabilizes urokinase-type plasminogen activator mRNA. Studies in vivo and in cell-free decay reactions.
    J Biol Chem. 1991 Nov 5;266(31):21190-6 PMID: 1939161
  10. Metalloproteinases and their inhibitors in matrix remodeling.
    Trends Genet. 1990 Apr;6(4):121-5 PMID: 2132731
  11. Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin.
    J Cell Biol. 1990 Apr;110(4):1361-7 PMID: 2139036
  12. Growth inhibition by TGF-beta linked to suppression of retinoblastoma protein phosphorylation.
    Cell. 1990 Jul 13;62(1):175-85 PMID: 2163767
  13. Independent expression and cellular processing of Mr 72,000 type IV collagenase and interstitial collagenase in human tumorigenic cell lines.
    Cancer Res. 1990 Oct 1;50(19):6184-91 PMID: 2169338
  14. Induction and stimulation of 92-kDa gelatinase/type IV collagenase production in osteosarcoma and fibrosarcoma cell lines by tumor necrosis factor alpha.
    Biochem Biophys Res Commun. 1990 Sep 14;171(2):610-7 PMID: 2169729
  15. Transforming growth factor beta stimulates mammary adenocarcinoma cell invasion and metastatic potential.
    Proc Natl Acad Sci U S A. 1990 Oct;87(19):7678-82 PMID: 2217201
  16. Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor.
    EMBO J. 1987 Jul;6(7):1899-904 PMID: 2820711
  17. A simple phase-extraction assay for chloramphenicol acyltransferase activity.
    Gene. 1988 Jul 30;67(2):271-7 PMID: 3169576
  18. Transforming growth factor beta increases mRNA for matrix proteins both in the presence and in the absence of changes in mRNA stability.
    Proc Natl Acad Sci U S A. 1988 Feb;85(4):1105-8 PMID: 3422482
  19. A conserved AU sequence from the 3' untranslated region of GM-CSF mRNA mediates selective mRNA degradation.
    Cell. 1986 Aug 29;46(5):659-67 PMID: 3488815
  20. Hormonal regulation of plasminogen activator mRNA production in porcine kidney cells.
    Cell. 1983 Apr;32(4):1181-90 PMID: 6687701
  21. Matrix metalloproteinases degrade insulin-like growth factor-binding protein-3 in dermal fibroblast cultures.
    J Biol Chem. 1994 Oct 14;269(41):25742-6 PMID: 7523391
  22. Ultraviolet B irradiation promotes tumorigenic and metastatic properties in primary cutaneous melanoma via induction of interleukin 8.
    Cancer Res. 1995 Aug 15;55(16):3669-74 PMID: 7543020
  23. mRNA stability in mammalian cells.
    Microbiol Rev. 1995 Sep;59(3):423-50 PMID: 7565413
  24. Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2).
    Cancer Res. 1995 Jun 15;55(12):2548-55 PMID: 7780967
  25. Activated gelatinase-B (MMP-9) and urokinase-type plasminogen activator in synovial fluids of patients with arthritis. Correlation with clinical and experimental variables of inflammation.
    J Rheumatol. 1995 Mar;22(3):385-93 PMID: 7783051
  26. Processing of tumour necrosis factor-alpha precursor by metalloproteinases.
    Nature. 1994 Aug 18;370(6490):555-7 PMID: 8052310
  27. Modulation of M(r) 72,000 and M(r) 92,000 type-IV collagenase (gelatinase A and B) gene expression by interferons alpha and gamma in human melanoma.
    Int J Cancer. 1994 Aug 15;58(4):582-6 PMID: 8056455
  28. Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells.
    Proc Natl Acad Sci U S A. 1994 May 10;91(10):4293-7 PMID: 8183903
  29. v-Src activates the expression of 92-kDa type IV collagenase gene through the AP-1 site and the GT box homologous to retinoblastoma control elements. A mechanism regulating gene expression independent of that by inflammatory cytokines.
    J Biol Chem. 1993 Nov 5;268(31):23460-8 PMID: 8226872
  30. Transforming growth factor-beta 1 stimulates glomerular mesangial cell synthesis of the 72-kd type IV collagenase.
    Am J Pathol. 1994 Jan;144(1):82-94 PMID: 8291614
  31. Interleukin-1 beta and transforming growth factor-alpha/epidermal growth factor induce expression of M(r) 95,000 type IV collagenase/gelatinase and interstitial fibroblast-type collagenase by rat mucosal keratinocytes.
    J Biol Chem. 1993 Sep 5;268(25):19143-51 PMID: 8395530
  32. Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells.
    Oncogene. 1993 Feb;8(2):395-405 PMID: 8426746
  33. Retroviral transduction of transforming growth factor-beta1 induces pleiotropic benign prostatic growth abnormalities in mouse prostate reconstitutions.
    Lab Invest. 1996 Apr;74(4):747-60 PMID: 8606485
  34. Stimulation of 92-kDa gelatinase B promoter activity by ras is mitogen-activated protein kinase kinase 1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP-1 sequences.
    J Biol Chem. 1996 May 3;271(18):10672-80 PMID: 8631874
  35. Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1.
    Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):7069-74 PMID: 8692946
  36. Transforming growth factor beta1 stimulates contrasting responses in metastatic versus primary mouse prostate cancer-derived cell lines in vitro.
    Cancer Res. 1996 Jul 15;56(14):3359-65 PMID: 8764134
  37. Expression of matrix metalloproteinase 9 (96-kd gelatinase B) in human rheumatoid arthritis.
    Arthritis Rheum. 1996 Sep;39(9):1576-87 PMID: 8814070
  38. Immunohistochemical studies of activated matrix metalloproteinase-2 (MMP-2a)expression in human prostate cancer.
    Oncol Res. 1996;8(2):63-7 PMID: 8859776
  39. Epidermal growth factor and amphiregulin up-regulate matrix metalloproteinase-9 (MMP-9) in human breast cancer cells.
    Int J Cancer. 1997 Mar 17;70(6):722-6 PMID: 9096655
  40. Correlation of metastasis-related gene expression with metastatic potential in human prostate carcinoma cells implanted in nude mice using an in situ messenger RNA hybridization technique.
    Am J Pathol. 1997 May;150(5):1571-82 PMID: 9137084
  41. Relating matrix metalloproteinase structure to function: why the "hemopexin" domain?
    Matrix Biol. 1997 Mar;15(8-9):511-8 PMID: 9138283
  42. The AP-1 site and MMP gene regulation: what is all the fuss about?
    Matrix Biol. 1997 Mar;15(8-9):519-26 PMID: 9138284
  43. Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants.
    EMBO J. 1997 May 1;16(9):2319-32 PMID: 9171346
  44. In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer.
    Clin Exp Metastasis. 1997 May;15(3):246-58 PMID: 9174126
  45. Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5.
    Science. 1997 Jul 11;277(5323):225-8 PMID: 9211848
  46. Posttranscriptional regulation of collagen alpha1(I) mRNA in hepatic stellate cells.
    Mol Cell Biol. 1997 Sep;17(9):5201-9 PMID: 9271398
  47. Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9).
    J Biol Chem. 1997 Nov 14;272(46):28823-5 PMID: 9360944
  48. Requirement for matrix metalloproteinase-9 (gelatinase B) expression in metastasis by murine prostate carcinoma.
    Am J Pathol. 1998 Feb;152(2):591-6 PMID: 9466586
  49. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity.
    Cell. 1998 Feb 6;92(3):391-400 PMID: 9476898
  50. Reduced lysyl oxidase messenger RNA levels in experimental and human prostate cancer.
    Cancer Res. 1998 Mar 15;58(6):1285-90 PMID: 9515817
  51. Tissue inhibitor of metalloproteinase-2 protection of matrix metalloproteinase-2 from degradation by plasmin is reversed by divalent cation chelator EDTA and the bisphosphonate alendronate.
    Cancer Res. 1998 Jul 15;58(14):2957-60 PMID: 9679953
Article Info
Journal
Molecular biology of the cell
Abbr.
Mol Biol Cell
ISSN
1059-1524
DOI
10.1091/mbc.10.2.407
Published
1999-02-00
Pages
407-16
Language
English
Region
United States
NLM ID
9201390
PMCID
PMC25177
Subset
IM
Grants
NCI NIH HHS · CA50588 · United States
NCI NIH HHS · F32 CA66323 · United States
External Links
PubMed source DOI: 10.1091/mbc.10.2.407 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2